Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-22	₩1,155.00	-5.48%	76,578
26-06-22	₩1,222.00	-10.80%	149,167
26-06-19	₩1,370.00	-6.36%	121,583
26-06-18	₩1,463.00	-0.41%	32,654
26-06-17	₩1,469.00	+1.87%	15,315

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-06-23			5-day change	1st Jan Change
1,155.00 ^KRW	-5.48%		-19.79%	-39.18%

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	20.87B 13.57M 11.86M 10.97M 10.24M 19.22M 1.28B 19.36M 130M 50.71M 630M 50.94M 49.84M 2.19B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	16.98B 11.04M 9.65M 8.92M 8.33M 15.64M 1.04B 15.75M 106M 41.26M 513M 41.46M 40.56M 1.78B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	67.36%	Yield 2024 *	-	Yield 2025	-

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
24-07-30	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
24-05-06	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-08	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
23-10-13	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
23-07-10	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
23-07-09	Genolution Inc. authorizes a Buyback Plan.	CI
23-05-15	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 day	-5.48%
1 week	-19.79%
Current month	-31.49%
1 month	-36.40%
3 months	-35.47%
6 months	-42.13%
Current year	-39.18%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation: Genolution Inc.

Chart: Genolution Inc.

Latest news : Genolution Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,149	1,499
1 month	1,149	1,826
Current year	1,149	2,120
1 year	1,149	2,830
3 years	1,149	5,140
5 years	1,149	10,891.09
10 years	1,000	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	2006-01-31
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Hak-Soo Lee BRD	Director/Board Member	70	2020-03-19
Dong-Seon Kim BRD	Director/Board Member	71	2025-03-27
Ki-Ok Kim BRD	Director/Board Member	71	2006-01-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-05-23	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
24-05-18	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	-5.48%	-19.79%	-53.05%	-72.73%	14.36M
VERACYTE, INC.	+0.32%	+5.01%	+100.19%	+109.44%	4.24B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+0.78%	+1.68%	+65.81%	+152.31%	2.78B
BGI GENOMICS CO., LTD.	-1.59%	+4.65%	-24.50%	-39.73%	2.07B
IOVANCE BIOTHERAPEUTICS, INC.	+5.54%	+12.43%	+132.16%	-46.78%	1.81B
CAREDX, INC.	-0.48%	+7.81%	+32.27%	+218.09%	1.29B
SEEGENE, INC.	-0.18%	-5.75%	-19.85%	+24.65%	813M
MARAVAI LIFESCIENCES HOLDINGS, INC.	+1.43%	+6.69%	+153.32%	-59.10%	774M
CURIOX BIOSYSTEMS CO., LTD	-14.23%	-34.88%	+22.85%	-	550M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+0.25%	-6.70%	-31.58%	-16.73%	500M
Average	-1.37%	-4.19%	+37.76%	+29.94%	1.49B
Weighted average by Cap.	+0.18%	+2.17%	+63.10%	+67.65%

	2024	2025
Net sales	7.14B 4.64M 4.05M 3.75M 3.5M 6.57M 438M 6.62M 44.56M 17.34M 216M 17.42M 17.04M 749M	9.4B 6.11M 5.34M 4.94M 4.61M 8.66M 578M 8.72M 58.73M 22.85M 284M 22.96M 22.46M 987M
Net income	-6.83B -4.44M -3.88M -3.59M -3.35M -6.29M -419M -6.33M -42.63M -16.59M -206M -16.66M -16.3M -716M	-11.64B -7.57M -6.61M -6.12M -5.71M -10.72M -715M -10.8M -72.71M -28.29M -352M -28.42M -27.81M -1.22B
Net Debt	-8.95B -5.82M -5.08M -4.7M -4.39M -8.24M -550M -8.3M -55.89M -21.75M -270M -21.85M -21.37M -939M	-3.89B -2.53M -2.21M -2.04M -1.91M -3.58M -239M -3.6M -24.27M -9.44M -117M -9.49M -9.28M -408M